Skip to main content
. 2020 Jun 10;12(2):133–136. doi: 10.1136/flgastro-2020-101502

Figure 1.

Figure 1

The mechanism of action of tofacitinib: (1) a cytokine binding to its cell surface receptor leads to receptor polymerisation; (2) tofacitinib inhibits the phosphorylation and activation of the Janus-associated tyrosine kinases (JAKs), JAK1 and JAK3; (3) JAKs cannot phosphorylate the cytokine receptors, therefore the receptors cannot dock signal transducers and activators of transcription (STATs); (4) as STATs are not phosphorylated or activated, gene transcription/cytokine production is inhibited.